INSTITUTIA MEDICO-SANITARA PUBLICA - INSTITUTUL DE PNEUMOLOGIE "CHIRIL DRAGANIUC"

Their core work

The Chiril Draganiuc Institute of Pneumology is Moldova's national pulmonary medicine research center, specializing in tuberculosis diagnosis, treatment, and control. They bring clinical expertise from a high-TB-burden country to European research consortia, contributing real-world patient data and trial sites for drug-resistant TB therapies. Their work spans TB diagnostics, host-directed treatment strategies, and cross-border HIV/TB/HCV response coordination across Eastern Europe.

What they specialise in

How they've shifted over time

All three projects started within a narrow window (2019-2020), so dramatic evolution is not visible. Early keywords show a broader diagnostic focus — latent TB detection and genotypic drug susceptibility — while the most recent project (DRTB-HDT, 2020) narrows toward therapeutic intervention for drug-resistant TB. This suggests a shift from diagnostic research toward treatment-oriented clinical trials.

Moving from diagnostic tools toward clinical intervention trials for drug-resistant TB, positioning themselves as a key Eastern European trial site for next-generation TB therapies.

How they like to work

Exclusively a participant — they have never coordinated an H2020 project, which is typical for institutions from Associated Countries like Moldova. They work in medium-to-large consortia (36 unique partners across 3 projects), suggesting they join broad international efforts rather than leading small targeted teams. This makes them a reliable specialist contributor who brings clinical access and patient cohorts from a high-burden TB setting.

Connected to 36 unique partners across 16 countries through just 3 projects, indicating participation in large pan-European health consortia. Their network likely spans Western European research universities and Eastern European clinical centers.

What sets them apart

As Moldova's national pneumology institute, they offer something Western European partners cannot easily replicate: direct clinical access to a high-TB-burden population, including drug-resistant cases. This makes them an essential partner for any consortium needing real-world trial sites, epidemiological data, or patient cohorts from Eastern Europe's TB frontline. For consortium builders targeting Widening or Global Health calls, they add both geographic diversity and clinical credibility.

Highlights from their portfolio

• DRTB-HDT
  Largest funding (EUR 313K) — a randomized controlled multi-center trial for host-directed therapy against drug-resistant TB, representing their deepest clinical research commitment.
• CARE
  Broadest scope — a cross-regional action against HIV/TB/HCV, connecting them to Europe-wide infectious disease policy and coordination networks.